Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Pharma China Annual Forum 2017

March 23, 2017 | China, Events, Patient journey, Pei Li Teh, Pharma China Annual Forum, emerging markets 

We are delighted to be presenting a paper at the Pharma China Annual Forum on 14th April 2017 in Shanghai, China.

Representing Research Partnership will be Asia Pacific Director and emerging markets specialist Pei Li Teh, who will be presenting the paper ’Urban China’s Evolving Patient Journey’ from 14:30 – 15:00. 

The patient is an important stakeholder in the treatment of chronic conditions in urban China. Patients, as well as their family members, play an important role in determining their own treatment. They decide when to present, they choose the hospital, many pay out of their own pocket for treatments and they are perhaps the key determinant in the duration of therapy. Therefore it is essential  to understand how the patient journey is evolving and the extent to which this will impact the pharmaceutical industry in the next 5 years. 

This paper will outline the universal truths of the chronic disease patient journey in China, as well as the key inflection points that have the biggest impact on treatment outcomes. Finally, by exploring the distinct healthcare challenges that China looks set to face, Pei Li will discuss the potential for pharma to address these challenges using a series of detailed case studies. 

Throughout the event Pei Li will be on hand to answer any questions you might have regarding our expertise and experience in emerging markets. If you are planning to attend the Pharma China Annual Forum and would like to meet with Pei Li, or are unable to attend but would be interested in receiving a copy of the paper please feel free to contact us.

Research Partnership is committed to staying at the cutting edge of healthcare research in emerging markets. As well as attending relevant conferences and exhibitions we are also regular speakers at relevant forums.

Find out more: http://bit.ly/2mXl6PY

This content was provided by Research Partnership

Company Details

- PMLiVE

Research Partnership

Email
Website

 Latest Content from  Research Partnership 

Blog: The Cost of Counterfeits

The sale of counterfeit drugs is growing at twice the rate of legitimate pharmaceuticals and pharma companies stand to lose more than just profits from the fallout of counterfeit identification.

Video: Self-pay and Emerging Markets

A key feature of emerging markets is that patients often have to pay for a high proportion of their healthcare costs themselves. For all but the most severe conditions, public...

News: Therapy Watch HCV expands into 4 additional EU markets

The HCV market has been growing and changing remarkably quickly and with the development of new and improving drugs, the treatment of HCV has moved on in a short space...

News: Research Partnership launches new patient report – Living with Ulcerative Colitis

Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5 EU markets (France, Germany, Italy, Spain...

Summer Intern experience at Research Partnership

We look for bright and inquisitive people who want to learn in a company that's pushing the boundaries of pharmaceutical market research

Beyond Andrology: Trends in Men’s Health in Emerging Markets

Published in eyeforpharma July 2016 by Rachel Howard

Infographic: HIV Market Snapshot

Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single...

Infographic: The vaccine opportunity in Asia

As predicted, the vaccine market in emerging and developing countries has continued to expand. While the global vaccine market is expected to grow at around 12% annually over the next...

Webinar: What next for biosimilars?

Tuesday 19th July 15:00 BST/10:00 EDT/16:00 CEST

Understanding the Patient Journey

The patient journey is changing. Patients are now much more educated and engaged. They have access to information and want to be involved in decisions around their treatment programme.  Technology...